Emyria Accelerates Mental Health Breakthroughs with $2.5M Raise and Leadership Shift

• Growing patient enrolment in MDMA-assisted PTSD therapy with zero drop-outs
• Ethics approval secured for psilocybin therapy targeting treatment-resistant depression
• Raised $2.525 million through placement to fund service expansion
• Leadership reshuffle with Greg Hutchinson as Executive Chairman and Dr. Michael Winlo as Chief Scientific Officer